Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$155.04 USD

155.04
7,145,777

-0.43 (-0.28%)

Updated Nov 11, 2024 04:00 PM ET

After-Market: $155.14 +0.10 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (57 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks News

Minerva-J&J's Amendment of MIN-202 Contract Wins EU Approval

The EU approves of Minerva's (NERV) amendment of MIN-202 license agreement with Janssen. Per the deal, Minerva will receive an upfront payment from Janssen.

    FDA Accepts Portola's (PTLA) BLA Resubmission for AndexXa

    FDA acknowledges Portola's (PTLA) resubmitted BLA for AndexXa to raise hopes for an urgent need of antidotes for Factor Xa inhibitors in the market.

      Catalyst (CPRX) Focused on Development of Pipeline Candidates

      Catalyst Pharmaceuticals, Inc. (CPRX) focuses on the development of its pipeline candidates Firdapse and CPP-115.

        Pacira Pharmaceuticals Focuses on Exparel's Label Expansion

        Pacira Pharmaceuticals, Inc. (PCRX) is making efforts to expand its flagship product, Exparel, which was launched in 2012.

          Geron (GERN) Q2 Loss Narrows, Sales Miss Estimates, Stock Up

          Geron Corporation (GERN) reported narrower-than-expected loss in Q2 while sales missed estimates. Shares were up in after-hours trading.

            Achillion (ACHN) Q2 Loss In Line, Gains on Pipeline Update

            Achillion Pharmaceuticals (ACHN) second-quarter loss was in-line with estimates. The company's shares surged almost 28% in after-market trading on positive pipeline results.

              Drug Stocks Q2 Earnings Roster for Aug 8: ACAD, JAZZ & More

              A look at the pharma/biotech companies that are set to report second-quarter results on Aug 8.

                Pacira (PCRX) Q2 Loss Wider than Expected, Revenues Miss

                Pacira Pharmaceuticals, Inc. (PCRX) remains confident about the prospects of its lead drug Exparel in Q2.

                  Pfizer (PFE) Surpasses Q2 Earnings Estimates, Misses Sales

                  Pfizer, Inc. (PFE) beat expectations for earnings while missing the same for sales in Q2. It raised the lower end of its 2017 adjusted earnings guidance but kept the revenue expectations intact.

                    Arpita Dutt headshot

                    Key FDA Events to Watch Out for in Aug 2017

                    Will the FDA follow the recommendation of its advisory panel and give its nod to Dynavax's (DVAX) hepatitis B vaccine?

                      The Zacks Analyst Blog Highlights: Johnson & Johnson, Merck and Co., McDonald's, Caterpillar and The Boeing Company

                      The Zacks Analyst Blog Highlights: Johnson & Johnson, Merck and Co., McDonald's, Caterpillar and The Boeing Company

                        Swarup Gupta headshot

                        Dow 30 Stock Roundup: Caterpillar, DuPont, MCD, P&G Beat

                        The Dow enjoyed a strong week of gains, riding on stellar earnings results.

                          AbbVie (ABBV) Tops Q2 Earnings & Revenues, Outlook Intact

                          AbbVie's (ABBV) Q2 earnings surpass estimates with revenues also marginally beating the same. Sales of its lead marketed drug, Humira, rise year over year.

                            United Therapeutics (UTHR) Incurs Loss in Q2, Sales Top

                            United Therapeutics Corporation (UTHR) incurred a loss in Q2. However, stronger sales across the PAH franchise pulled up the top line in the quarter.

                              Is a Beat in the Cards for Pfizer (PFE) in Q2 Earnings?

                              While Pfizer, Inc.'s (PFE) new drugs like Ibrance and acquisitions like Hospira are likely to drive sales in Q2, genericization of key drugs, pricing pressure and rising competition will hurt sales.

                                Biotech Stocks Jul27 Q2 Earnings Roster: BMY, CELG & ALXN

                                Bristol-Myers Squibb Company (BMY), Celgene (CELG) and Alexion Pharma (ALXN) are set to report second-quarter results on Jul 27.

                                  Biogen (BIIB) Tops Q2 Earnings & Sales, Spinraza Sales Up

                                  Biogen Inc. (BIIB) surpassed expectations both for earnings and sales in the second quarter of 2017. The MS drugmaker also raised its revenue guidance for 2017 on the back of strong Spinraza sales.

                                    Drug Stocks Q2 Earnings Releases on Jul 26: GILD, VRTX, GSK

                                    We have three pharma giants that are set to report second-quarter results on Jul 26. Let's see how things are shaping up for this quarter.

                                      What's in the Cards for Geron (GERN) this Earnings Season?

                                      Investors will be looking at Geron's progress with its hematologic myeloid malignancies pipeline candidate, Imetelstat.

                                        Big Pharma Q2 Earnings Releases on Jul 25: LLY, BIIB, AMGN

                                        Three pharma giants are set to report second-quarter results on Jul 25. Let's see how things are shaping up for this quarter.

                                          AbbVie Inc's. (ABBV) Q2 Earnings: Disappointment in Store?

                                          AbbVie's (ABBV) key drugs, Humira and Imbruvica, might lead the company toward an earnings beat in Q2 despite a negative Earnings ESP posing a threat to the stock.

                                            The Zacks Analyst Blog Highlights: Johnson & Johnson, Coca-Cola, Honeywell, Crown Castle and WEC Energy

                                            The Zacks Analyst Blog Highlights: Johnson & Johnson, Coca-Cola, Honeywell, Crown Castle and WEC Energy

                                              Sweta Killa headshot

                                              J&J Brightens Outlook: Healthcare ETFs in Focus

                                              Johnson & Johnson continued its long streak of earnings beat and offered an upbeat outlook for the full year. However, it lagged our revenue estimate.

                                                Company News for July 19, 2017

                                                Companies in the News are: JNJ,BAC,UNH,CMG

                                                  Gilead's HCV Portfolio Receives a Boost With Vosevi Approval

                                                  Gilead's (GILD) HCV portfolio received a boost with the FDA's approval of its once-daily HCV regimen, Vosevi.